Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	GASPAR N. MARSHALL L.V. BINNER D. HEROLD R. ROUSSEAU R. BLANC P. CAPDEVILLE R. CARLEER J. COPLAND C. KERLOEGUEN Y. NORGA K. PACAUD L. SEVAUX M.A. SPADONI C. ŠTĚRBA Jaroslav LIGAS F. TAUBE T. UTTENREUTHER-FISCHER M. CHIOATO S. O'CONNELL M.A. GEOERGER B. BLAY J.Y. SORIA J.C. KAYE S. WULFF B. BRUGIERES L. VASSAL G. PEARSON ADJ
Year of publication	2018
Type	Article in Periodical
Magazine / Source	Annals of Oncology
MU Faculty or unit	Faculty of Medicine
Citation
Web	http://dx.doi.org/10.1093/annonc/mdy002
Doi	http://dx.doi.org/10.1093/annonc/mdy002
Keywords	PEDIATRIC-PATIENTS; HODGKINS-LYMPHOMA; SOLID TUMORS; YOUNG-ADULTS; ONCOLOGY; CHILDREN; PARTICIPATION; APPROPRIATE; TEENAGERS; RECURRENT
Description	The impressive progress recently observed in adult cancers through the introduction of new drugs has not yet been translated to adolescents 12-17 years of age [defined according to the International Conference on Harmonization (ICH) E11]. The current drug development landscape separates adult and paediatric drug development (Table 1). Adolescents are grouped with children, leading to a mismatch with a lack of trials for adolescents with relapsed cancer and delayed access to new, effective drugs already available for adults.
Related projects:	Sekvenování nové generace a expresní profilování jako diagnostický podklad pro návrhy individualizovaných léčebných plánů pro děti se solidními nádory Receptorové tyrozinkinázy a navazující signální dráhy jako potenciální cíle léčby refrakterních solidních nádorů dětského věku